Ashoka Institute of Technology and Management, Ashoka Engineering Chauraha, Paharia Sarnath Road, Sarnath, Varanasi, Uttar Pradesh, India.
Institute of Pharmaceutical Research (IPR), GLA University, Mathura, NH-2, Mathura Delhi Road, Chaumuhan Mathura, Uttar Pradesh, India.
Recent Pat Nanotechnol. 2023;17(4):359-377. doi: 10.2174/1872210516666220819104853.
COVID-19, caused by the SARS-CoV-2 virus, has been expanding. SARS-CoV caused an outbreak in early 2000, while MERS-CoV had a similar expansion of illness in early 2010. Nanotechnology has been employed for nasal delivery of drugs to conquer a variety of challenges that emerge during mucosal administration. The role of nanotechnology is highly relevant to counter this "virus" nano enemy. This technique directs the safe and effective distribution of accessible therapeutic choices using tailored nanocarriers, as well as the interruption of virion assembly, by preventing the early contact of viral spike glycoprotein with host cell surface receptors. This study summarises what we know about earlier SARS-CoV and MERS-CoV illnesses, with the goal of better understanding the recently discovered SARS-CoV-2 virus. It also explains the progress made so far in creating COVID-19 vaccines/ treatments using existing methods. Furthermore, we studied nanotechnology- based vaccinations and therapeutic medications that are now undergoing clinical trials and other alternatives.
由 SARS-CoV-2 病毒引起的 COVID-19 正在蔓延。SARS-CoV 于 21 世纪初引发了一次疫情，而 MERS-CoV 于 21 世纪 10 年代初也发生了类似的疾病爆发。纳米技术已被用于经鼻给药，以克服黏膜给药时出现的多种挑战。纳米技术在对抗这种“病毒”纳米敌人方面发挥着重要作用。该技术通过使用定制的纳米载体安全有效地分配可及的治疗选择，并通过防止病毒刺突糖蛋白与宿主细胞表面受体的早期接触来阻止病毒粒子的组装，从而发挥作用。本研究总结了我们对早期 SARS-CoV 和 MERS-CoV 疾病的认识，以期更好地了解最近发现的 SARS-CoV-2 病毒。它还解释了迄今为止使用现有方法在开发 COVID-19 疫苗/治疗方面所取得的进展。此外，我们研究了正在进行临床试验和其他替代方案的基于纳米技术的疫苗接种和治疗药物。
